
|Articles|March 3, 2008
Post-marketing liver injury reports lead to Tysabri PI update
Liver injury warnings added to natalizumab prescribing information.
Advertisement
Reports of markedly elevated serum hepatic enzymes and elevated total bilirubin in patients receiving natalizumab (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
2
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5







































